Supplementary Material for: Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial by figshare admin karger (2628495)

“…Grade 3-4 treatment-related adverse events occurred in 79.5% of the subjects, with the most common being decreased neutrophil count (41%), decreased platelet count (30.8%), and increased aspartate aminotransferase (23.1%). …”

<b>Keystone taxa and microbial network complexity, rather than diversity, sustain soil multifunctionality along an elevational gradient in a subtropical karst mountain</b> by Weixue Luo (6070040)

“…Notably, the positive effects of network complexity and keystone taxa abundance on soil EMF decreased with increasing threshold levels of EMF, yet keystone taxa abundance retained a significant positive effect even at the highest threshold (75%). …”

DataSheet1_Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.docx by Cuilin Que (19743256)

“…Background<p>Stroke is a serious health issue that can result in death or disability, leading to a significant economic strain on society and families. …”

Table 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 1_The trajectory of intrinsic capacity and its related factors among elderly Chinese patients with cardiovascular disease: a prospective cohort study.docx by Yanyin Cui (21428879)

“…</p>Results<p>The GBTM model identified three categories of IC trajectories among elderly patients with CVD: the low-decreased group (n=162, 23.11%), the high-increased group (n=196, 27.96%), and the medium-stable group (n=343, 48.93%). …”

Supplementary Material for: Endoscopic Anti-reflux Mucosal Interventions for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Compara... by figshare admin karger (2628495)

“…Results: Technical success was 100%, with a mean procedure time of 42.09 minutes. ARMIs significantly reduced the proportion of patients using PPI (RR=2.22-3.06; <3–24 months; P≤0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (P<0.05). …”

Supplementary file 1_Burden of ageing spectrum of diseases in China, 1990–2021: a systematic analysis of global burden of disease study 2021.pdf by Li Yang (6520)

“…Background<p>Population aging represents a pressing challenge for China, given its vast population and the growing proportion of adults aged 65 years and older. …”

Tobacco and alcohol use are the risk factors responsible for the greatest burden of head and neck cancers: a study from the Global Burden of Disease Study 2019 by Yue Yuan (113839)

“…Interestingly, the ASIRs for laryngeal cancer showed a decreasing trend over the studied time frame from 1990 to 2019. …”

Table 2_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 3_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

<i>ADH7, FABP5, ALDH1A1, CRABP-2, PPARγ</i> and <i>VEGFA</i> mRNA and ADH7, FABP5, CRABP-2, PPARγ and VEGFA protein levels in limbal stromal cells (LSCs) and aniridia limbal stroma... by Shuailin Li (11907158)

“…<i>ADH7, FABP5</i> and <i>VEGFA</i> mRNA levels were significantly higher in AN-LSCs, than in LSCs (p ≤ 0.037) while ADH7 protein level was significantly lower in AN-LSCs, than in LSCs (p = 0.022) <b>(A, B, D, O)</b>. …”

Table 1_A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice.docx by Yi Pan (68170)

“…In the PPC group, baseline alanine transaminase (ALT) levels decreased at 12- and 24-weeks compared to those of the control group, but results were not significant. …”

Video 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

“…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Video 2_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

“…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Table 1_A cohort-based assessment of drug use trends during the COVID-19 pandemic: relationship with mood and sociodemographic factors in Brazil.docx by Nubia Heidrich (14079741)

“…<p>The COVID-19 pandemic has brought significant challenges, including severe psychological consequences, especially for vulnerable individuals, such as those with substance use disorders. …”

Image 3_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 2_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 4_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Table 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.docx by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”